Molecular Partners Reports Corporate Highlights and Key Financials for H1 2020

August 26, 2020 1:00 AM

Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial in vitro and in vivo data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen. Secured partnership with AGC Biologics to meet initial projected clinical and commercial-scale manufacturing capacity for anti-COVID-19...

Read more

Hancock Jaffe Enrolls Initial Patients for First-in-Human CoreoGraft Study

August 25, 2020 11:00 AM

Two of Five Patients Enrolled for the Study IRVINE, CA / ACCESSWIRE / August 25, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enrolled the first two patients for its first-in-human CoreoGraft study. The first implant of the CoreoGraft conduits will take place in the coming weeks and HJLI will announce the schedule when available. The...

Read more

Experion Set to Introduce Vegan Gummies Under Citizen Stash

August 25, 2020 8:45 AM

Experion Signs Supply Agreement with Lyf Food Technologies Inc. VANCOUVER, BC / ACCESSWIRE / August 25, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce it has signed a supply agreement with Lyf Food Technologies Inc. ("Lyf") for the supply of high quality edible cannabis products. Under the terms of the Agreement, Lyf Food Technologies...

Read more

PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the EASL | Digital International Liver Congress 2020

August 24, 2020 4:00 PM

PRINCETON, NJ / ACCESSWIRE / August 24, 2020 / ​​​​​PharmaNest is an image analysis company focused in the development and validation of novel standards for the quantification of Fibrosis and associated histological features for drug discovery and development. Recently, PharmaNest announced the launch of its FibroNest cloud-based and multi-vendor platform for the automated quantification of Fibrosis for non-alcoholic fatty liver disease (NAFLD)...

Read more

Nascent Biotech Inc Completes $740,000 Equity Round of Funding

August 24, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 24, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) announced today that it is closing on a direct private placement with aggregate proceeds of $740,000. The proceeds allow the Company to complete the required testing for removing the partial clinical trial hold, imposed by the FDA, and will permit the company to begin the Phase I clinical trials on brain cancer. Sean Carrick, CEO of Nascent commented,...

Read more

Wuhan General Group Corporate Update

August 21, 2020 11:45 AM

CAPE TOWN, SA / ACCESSWIRE / August 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share the following corporate update: Supply Chain, Operations and Covid-19: August 18th, South Africa transitioned from level 3 lockdown to level 2 with many restrictions being lifted...

Read more

Hancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve Patients

August 21, 2020 8:30 AM

VenoValve Patients Continue to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / August 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that two additional VenoValve patients from HJLI's first-in-man, clinical study in Colombia have now reached the one-year milestone following VenoValve surgery, and that chronic...

Read more

Rising Biosciences, Inc. Announces Shareholder Conference Call, Wednesday, August 26th

August 20, 2020 9:00 AM

SANDUSKY, OH / ACCESSWIRE / August 20, 2020 / Rising Biosciences, Inc. (OTC PINK:RBII) CEO Arthur Hall is extending an invitation to a shareholder conference call at 4:30 PM EDT on Wednesday, August 26th. "Shareholders and people following RBII are invited to participate", said Hall. "We have experienced solid growth in 2020 and we're excited to answer questions, share our enthusiasm and discuss what the coming months will...

Read more

Lexaria Bioscience to Present at the LD 500 Virtual Conference

August 20, 2020 7:17 AM

Company to discuss its Phase I R&D program with Altria Ventures Inc., for oral forms of nicotine delivery utilizing its patented DehydraTECH™ technology LOS ANGELES, CA / ACCESSWIRE / August 20, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it will be presenting at the 12th annual LD 500 Conference on...

Read more

National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

August 18, 2020 4:24 PM

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / August 18, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for...

Read more

Green Leaf Farms International Signs Joint Venture Agreement with ST Biosciences for Its Project in Argentina

August 18, 2020 8:30 AM

The Agreement includes an investment of $1.2 million and distribution of GLFIs products to ST Biosciences International Customers LAS VEGAS, NV / ACCESSWIRE / August 18th, 2020 / GLFI, Inc., doing business as Green Leaf Farms International a privately held company that is a majority owned subsidiary of Players Network, Inc. (OTC PINK:PNTV), which has been established to finance and manage international cannabis operations outside North...

Read more

AzurRx BioPharma to Present at The LD 500 Virtual Conference

August 18, 2020 8:00 AM

LOS ANGELES, CA / ACCESSWIRE / August 18, 2020 / AzurRx BioPharma, Inc. (NASDAQ:AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will be presenting at the LD 500 investor conference on Tuesday, September 1st at 2:20 PM Eastern Time/11:20 AM Pacific Time. AzurRx CEO and President James Sapirstein will be presenting to a live virtual audience and will be...

Read more

Tetra Bio-Pharma Engages Dalton Pharma for GMP Manufacturing of ARDS-003

August 18, 2020 8:00 AM

Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug product A new anti-inflammatory drug candidate OTTAWA, ON / ACCESSWIRE / August 18, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has awarded the contract for the manufacturing of its...

Read more

Tetra Bio-Pharma and Mondias Enter Into Final Agreement For The Purchase Of Lumiera Health Innovation Inc.

August 17, 2020 8:30 AM

MONTREAL, QC / ACCESSWIRE / August 17, 2020 / Mondias Natural Products Inc. (TSXV:NHP) (the "Company" or "Mondias") specializing in evidence-based natural products for the healthcare and bio-agriculture markets and Tetra Bio-Pharma Inc. ("Tetra"), (TSX-V:TBP) (OTCQB:TBPMF), a biopharmaceutical leader in the discovery and development of cannabinoid-derived therapeutics are pleased to announce they are entering into...

Read more

Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress

August 13, 2020 4:30 PM

Entered into two new collaborations with top tier animal health companiesEntered into a fully funded human health collaboration with a top five global pharmaceutical companyStarted an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soonDyadic selected by Frederick National Laboratory to engineer several C1 cell lines to express COVID-19 vaccine candidatesEntered into a new...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 13, 2020 7:05 AM

- Successfully established two strategic academic collaborations in Q2 2020 to advance development of XCART™, its differentiated CAR T therapy platform - - Strengthened panel of experts on the Scientific Advisory Board, bringing valuable expertise across all phases of preclinical and clinical development - FRAMINGHAM, MA / ACCESSWIRE / August 13, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the...

Read more

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

August 12, 2020 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt")...

Read more

Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results

August 12, 2020 7:45 AM

TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business. During the quarter, Edesa received Canadian regulatory approval to begin a Phase 2/Phase 3 clinical study of its biologic drug candidate, EB05, as a potential treatment for hospitalized COVID-19...

Read more

Nascent Biotech Reduces Liabilities by Over 1.8 Million Dollars

August 11, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 11, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has significantly reduced its liabilities through stock conversion and payment of accrued liabilities. The reduction was achieved through the conversion of $1,600,000 in debt to equity and the payment of over $200,000 of liabilities. Nascent's CFO Lowell Holden stated, "I believe the Company has continued to be undervalued...

Read more

Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin(R) Program

August 11, 2020 1:00 AM

Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use Purchase of these doses may occur following appropriate marketing authorization Multi-specific antiviral program demonstrates best-in-class potency against live SARS-CoV-2 virus; Recent in vivo data additionally supportive of clinical...

Read more